Orally-delivered insulin-peptide nanocomplexes enhance transcytosis from cellular depots and improve diabetic blood glucose control
Journal of Controlled Release · 2023-08 · 360 · 93-109
DOI: 10.1016/j.jconrel.2023.06.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-08. Verfasst von Sahrish Rehmani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regenerative Medicine & Cellular Therapies, The University of Nottingham Biodiscovery Institute (BDI), School of Pharmacy, University of Nottingham, …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Cell-Penetrating Peptides. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Insulin regulates blood glucose levels, and is the mainstay for the treatment of type-1 diabetes and type-2 when other drugs provide inadequate control. Therefore, effective oral Insulin delivery would be a significant advance in drug delivery. Herein, we report the use of the modified cell penetrating peptide (CPP) platform, Glycosaminoglycan-(GAG)-binding-enhanced-transduction (GET), as an efficacious transepithelial delivery vector in vitro and to mediate oral Insulin activity in diabetic animals. Insulin can be conjugated with GET via electrostatic interaction to form nanocomplexes (Insulin GET-NCs). These NCs (size and charge; 140 nm, +27.10 mV) greatly enhanced Insulin transport in differentiated in vitro intestinal epithelium models (Caco2 assays; >22-fold increased translocation) with progressive and significant apical and basal release of up-taken Insulin. Delivery resulted in intracellular accumulation of NCs, enabling cells to act as depots for subsequent sustained release without affecting viability and barrier integrity. Importantly Insulin GET-NCs have enhanced proteolytic stability, and retained significant Insulin biological activity (exploiting Insulin-responsive reporter assays). Our study culminates in demonstrating oral delivery of Insulin GET-NCs which can control elevated blood-glucose levels in streptozotocin (STZ)-induced diabetic mice over several days with serial dosing. As GET promotes Insulin absorption, transcytosis and intracellular release, along with in vivo function, our simplistic complexation platform could allow effective bioavailability of other oral peptide therapeutics and help transform the treatment of diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regenerative Medicine & Cellular Therapies, The University of Nottingham Biodiscovery Institute (BDI), School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK.
- Diabetes Research Centre, School of Biomedical Sciences, Ulster University, Coleraine, Co. Londonderry BT52 1SA, UK.
- Regenerative Medicine & Cellular Therapies, The University of Nottingham Biodiscovery Institute (BDI), School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK. Electronic address: james.dixon@nottingham.ac.…
Förderung
- Medical Research Council
Zitieren
APA
Rehmani, S., McLaughlin, C. M., Eltaher, H. M., Moffett, R. C., Flatt, P. R., & Dixon, J. E. (2023). Orally-delivered insulin-peptide nanocomplexes enhance transcytosis from cellular depots and improve diabetic blood glucose control. Journal of Controlled Release, 360, 93-109. https://doi.org/10.1016/j.jconrel.2023.06.006
Vancouver
Rehmani S, McLaughlin CM, Eltaher HM, Moffett RC, Flatt PR, Dixon JE. Orally-delivered insulin-peptide nanocomplexes enhance transcytosis from cellular depots and improve diabetic blood glucose control. Journal of Controlled Release. 2023;360:93-109. doi:10.1016/j.jconrel.2023.06.006
BibTeX
@article{Rehmani2023,
author = {Rehmani, Sahrish and McLaughlin, Christopher M and Eltaher, Hoda M and Moffett, R Charlotte and Flatt, Peter R and Dixon, James E},
title = {Orally-delivered insulin-peptide nanocomplexes enhance transcytosis from cellular depots and improve diabetic blood glucose control},
journal = {Journal of Controlled Release},
year = {2023},
volume = {360},
pages = {93--109},
doi = {10.1016/j.jconrel.2023.06.006}
}
EUVIMED